---
title: MedTech Startup Valuation: How Regulatory Milestones Drive Enterprise Value
description: MedTech valuations are anchored to regulatory milestones more than to revenue. Here is how each milestone moves the value.
authors: Tibor Zechmeister, Felix Lenhard
category: Funding, Business Models & Reimbursement
primary_keyword: MedTech startup valuation regulatory milestones
canonical_url: https://zechmeister-solutions.com/en/blog/medtech-startup-valuation-regulatory-milestones
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# MedTech Startup Valuation: How Regulatory Milestones Drive Enterprise Value

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **MedTech startup valuation is anchored to regulatory milestones more than to revenue. Each milestone — intended purpose locked, Notified Body engaged, technical file submitted, CE certificate issued under MDR Article 56, PMCF data landing, first hospital paying, first reimbursement coverage, multi-country scale — corresponds to a discrete step-up in enterprise value that specialist investors and acquirers price independently of the growth curve. Founders who understand the step function can plan the round that clears the next bump. Founders who treat valuation as a smooth function of headcount and aspiration raise the wrong rounds at the wrong times and discover the mismatch at exit.**

**By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.**

---

## TL;DR

- MedTech enterprise value moves in discrete steps tied to regulatory milestones, not in a smooth curve tied to MRR. The steps are predictable and can be planned against.
- A CE certificate issued under MDR Article 56 is a transferable asset and one of the largest single valuation step-ups in a MedTech company's life.
- The value bumps at each stage — intended purpose, NB engaged, technical file submitted, CE issued, first revenue, first hospital, reimbursement secured, scale — are not linear. CE mark and first reimbursement contract are typically the two largest.
- Missing a milestone on the expected timeline creates a valuation discount that compounds through every subsequent round. The discount is not the investor being harsh — it is rational repricing of regulatory risk.
- Acquirers translate regulatory assets into valuation by pricing avoided cost and avoided time. A live QMS under EN ISO 13485:2016+A11:2021 and a clean technical file save them years.
- Regulatory due diligence at exit follows a consistent pattern. Founders who prepare the asset register early survive it without discount. Founders who do not absorb the discount in the final term sheet.

---

## Why MedTech valuation is milestone-driven

A SaaS company is valued on a smooth function of growth, retention, and margin. The curve goes up as MRR goes up. Investors argue about the multiple, but the underlying logic is continuous — every additional paying customer adds marginal value the same way.

MedTech does not work like this, and founders who carry the SaaS intuition into a MedTech cap table get hurt by the difference. A MedTech company's value moves in discrete steps, and the steps are anchored to regulatory events. Before CE mark, the device cannot legally be sold at scale in Europe, so revenue is not the valuation driver — the probability and timing of CE mark is. After CE mark, the device can be sold, but without reimbursement, customers cannot afford it sustainably, so commercial traction depends on payer progress. Each of these events is binary. Either the certificate is in hand or it is not. Either the payer contract is signed or it is not. Either the PMS data is landing or it is not.

Specialist MedTech investors price this explicitly. They build their models around regulatory milestones because the milestones are what the underwriting actually depends on. An investor who funds a company at "Series A, pre-CE" is pricing a different asset than an investor who funds the same company at "Series A, post-CE, first hospital contract signed" — even if the revenue number on the slide is identical. The milestone between these two states is worth more than any amount of pre-CE traction, because it turns a risk into an asset.

This is also why SaaS-trained investors who wander into MedTech rounds often misprice them. They see headcount, a deck, a growth story, and they anchor on a SaaS comparable. The specialist investor in the same meeting is pricing the regulatory step function and sees a completely different number. The founder who aligns with the specialist logic wins the round and the subsequent rounds. The founder who aligns with the SaaS frame raises once at an inflated mark and struggles every round after.

## The value bumps at each stage

The step function in a MedTech company's life has identifiable stages. Not every company goes through every one, and the relative size of each bump depends on the device class, the target market, and the therapeutic area — but the pattern is consistent enough to plan against.

**Intended purpose locked and classification defensible.** The first real bump. Before this, the company is an idea. After this, the regulatory path is visible and the total cost of the journey can be estimated. Investors who see a vague intended purpose see a company that has not done the basic work. Investors who see a tight intended purpose with a named classification and the specific Annex VIII rule cited see a team that knows where it is going. The bump is small in absolute terms but large in probability — it is the moment the company becomes fundable at all.

**Notified Body engaged and contract signed.** A meaningful bump. Notified Body capacity has been a bottleneck for years, and a signed engagement letter is a tangible asset. Companies without an NB on contract discount against companies with one, because the NB timeline is often longer than the founder expected and the round's runway depends on it.

**Technical file substantially complete and submitted.** Another bump, and a larger one. At this point the company has moved from "planning" to "under review." The regulatory uncertainty narrows. The round that funds this submission is cheaper than the round that funds the later steps, because the risk that remains is concrete and time-bound rather than open-ended.

**CE certificate issued.** The largest single step in most MedTech valuation curves. Under MDR Article 56, the Notified Body issues a certificate that permits the device to be placed on the market, and that certificate is the asset that unlocks every subsequent step. Enterprise value typically step-changes at CE issuance by a multiple, not a percentage. This is why a round that clears CE is priced so differently from a round that funds the run at CE — the binary event sits between them.

**First hospital paying.** The first real customer is worth more than any number of pilots or letters of intent. It converts the commercial story from assertion to evidence. Specialist investors will pull the contract in diligence and read it.

**First reimbursement coverage.** Comparable in size to CE mark itself in many categories. A paying customer without reimbursement is a one-off sale. A paying customer with reimbursement is the beginning of a repeatable commercial motion. The payer decision — a DiGA listing, a NICE coverage determination, a national insurance code — turns the business model from fragile to durable.

**PMCF data landing and PMS system credible.** Post-market clinical follow-up and post-market surveillance are not valuation headlines, but missing them creates discounts. An acquirer's regulatory due diligence will check that the PMS system is running, that vigilance reporting is in place, and that PMCF data is being collected per the plan. Clean PMS is the difference between a valuation held and a valuation discounted.

**Multi-country scale.** The final bump, typically preceding exit conversations. Revenue in more than one market, reimbursement in at least two, a technical file that has survived at least one NB surveillance audit — this is the state in which a trade sale produces the outcomes that early investors were underwriting to.

## The discount for missing milestones

The flip side of the step function is that missing a milestone on the expected timeline is not a small problem. It is a compounding one.

When a company's CE mark slips from quarter three to the following year, the investor does not just push the valuation curve out by three quarters. The investor reprices the underwriting. The probability of the next slip rises. The cash runway assumptions change. The competitive landscape the company expected to enter may have moved. The next round, if it happens, happens at a lower valuation than the plan anticipated — sometimes materially lower — because the risk profile is no longer what the prior round priced.

This is the pattern behind most down rounds in European MedTech. The company raised Series A against a CE mark expected in 12 months. CE mark arrived at 20 months. The Series B, which was supposed to fund commercial launch at a step-up, instead funded the final months of the CE mark push at a lower mark. The cap table damage is permanent, and the dilution disproportionately hits the earliest believers.

The founders who avoid this pattern do one thing consistently. They plan the round against the honest timeline, not the optimistic one, and they add Felix's doubling rule as buffer. A round that funds the plan plus buffer survives the slip that will happen. A round that funds the optimistic plan triggers a bridge at the exact moment the company can least afford it, and every subsequent round is harder for it.

The other pattern worth naming is the milestone that arrives on time but without the supporting assets. A CE certificate issued against a technical file full of open findings is not the same asset as a CE certificate issued against a clean file. The milestone is nominally achieved, but the next acquirer or Notified Body surveillance audit will surface the gaps, and the discount lands then instead of earlier. Clean beats clever, at every milestone.

## How acquirers translate regulatory assets into valuation

Acquirers price MedTech regulatory assets by the cost and time they save. This is the most concrete way to understand enterprise value at exit.

A live, audited QMS under EN ISO 13485:2016+A11:2021 is worth what it would cost the acquirer to build one from scratch, minus the cost of integrating the existing one into their structure. That number is not trivial — building a QMS that passes audit takes many months and substantial money, and the risk of building it wrong is real.

A CE certificate under MDR Article 56 is worth what it would cost the acquirer to re-certify the product under their own name if the transfer were not possible — which, for an innovative device, is often the total cost of the original regulatory project plus the delay to market. The Notified Body change-of-ownership process is doable but not automatic; it must be planned into the deal, and the cost of planning badly is far higher than the cost of planning well.

A clean, current technical file under Annex II is worth what it would cost the acquirer to compile the same documentation from the original design history, risk file, verification data, and clinical evidence — work that cannot usually be redone without the team that did it the first time.

A PMS system with live data landing is worth the acquirer's avoided risk on the next surveillance audit and their avoided cost of standing up a compliant PMS function inside their existing structure.

Sophisticated acquirers quantify each of these. They come to the table with an internal number for what each asset would cost them to build or rebuild, and they use that number as the valuation floor for the asset. Founders who know this can negotiate from the same frame. Founders who do not are often negotiating against a number they cannot see.

## The regulatory due diligence pattern

Regulatory due diligence at exit or at a growth round follows a consistent pattern, and founders who prepare for it well in advance survive it without discount. The pattern has a shape.

First, the acquirer or lead investor retains regulatory counsel or a specialist advisor to review the technical file, the QMS, the CE certificate, the NB correspondence, the PMS data, and the vigilance record. This review is not a formality. It is a root-cause analysis looking for gaps that would become acquirer liabilities after closing.

Second, the review produces a findings list. Minor findings become remediation items handled before closing. Material findings become valuation adjustments — direct reductions in the headline mark, or structural changes that shift value from the founder to the acquirer via earn-outs and escrows tied to post-close remediation.

Third, the findings are cross-checked against the NB's own record. If the NB has issued an observation letter in the past 18 months that the founder did not disclose, the deal stalls or dies. Founders who think they can omit unflattering NB correspondence from the data room are wrong. The NB is a regulated third party, and the acquirer will reach them.

Fourth, the PMS data is tested against the PMS plan. Is the system actually collecting what the plan said it would collect? Is the data being used to update the clinical evaluation? Are the vigilance obligations under Article 87–92 being met on the required timelines? This is where founders who treat PMS as a binder exercise get exposed.

Fifth, the IP is cross-checked against the regulatory documentation. Contractors who contributed to the design history without a clean assignment become a deal blocker. Open-source components in the software stack without proper licensing become a deal blocker. Founders who did the IP hygiene at the start of the company sail through this. Founders who did not spend weeks of the final diligence fixing paperwork under time pressure.

The survivable version of this process is the one where the founder's regulatory work has been maintained as an asset register from day one — every document, every audit, every certificate, every correspondence logged and retrievable. The expensive version is the one where the founder tries to reconstruct the record under diligence pressure while the acquirer's advisor watches.

## Common founder mistakes

The errors that show up at MedTech valuation conversations repeat. A few specific ones are worth naming.

**Pricing the round against headcount instead of against the next milestone.** Investors translate headcount into milestone progress anyway. The founder loses nothing by leading with the milestone frame directly.

**Inflating the mark at a pre-milestone round.** The higher mark feels like a win at the time, but the next round becomes a trap when the milestone slips, as it usually does. A clean lower mark is often worth more than a proud higher one.

**Treating regulatory work as cost, not as capital expenditure on a future asset.** Every euro spent on a clean QMS, a traceable technical file, or a working PMS system shows up in the exit valuation later. Founders who do not see the link underinvest in the wrong places.

**Ignoring the reimbursement milestone in the valuation plan.** In many categories, the first reimbursement contract is worth as much as CE mark itself. A fundraising plan that does not budget for the payer work is a plan that will raise the wrong round size.

**Hiding bad news in the data room.** Every acquirer reads the data room with adversarial care. Omissions surface. Disclosed problems are negotiable. Discovered problems are discount arguments.

**Failing to maintain the asset register as the company grows.** The cost of building the register in real time is small. The cost of reconstructing it under diligence pressure is large, and the reconstruction itself introduces errors that the acquirer finds and prices in.

## The Subtract to Ship angle

[Subtract to Ship](/blog/subtract-to-ship-framework-mdr) applied to valuation says the same thing it says everywhere else: strip the work that does not contribute to the outcome, and concentrate the work that does. For valuation, the outcome is the milestone step-up. Every euro of spend, every hire, every activity should trace to progress against the next regulatory milestone or to the maintenance of an asset that the next milestone depends on. Everything else is dilution without valuation support.

This is not a counsel of thinness. It is a counsel of focus. The company that spends heavily on the work that clears the milestone and sparingly on the work that does not will reach the step-up faster and at a lower total burn than the company that spreads spend across everything at once. The first company raises the next round at a step-up. The second company runs out of runway before the milestone arrives.

Tibor's framing applies directly: more money thrown at a milestone does not make it arrive sooner if the underlying plan is not real. The valuation does not move just because the round is larger. It moves because the milestone actually clears.

## Reality Check — Where do you stand?

1. Can you name the next three regulatory milestones your company will clear, with the expected timeline and the cost of reaching each one on the doubled honest estimate?
2. Is your current round sized to clear the next milestone plus a realistic buffer, or to fund a headcount plan that may or may not produce the milestone?
3. If you were acquired tomorrow, is your technical file, QMS, and CE certificate status ready to survive regulatory due diligence without visible gaps?
4. Do you maintain a regulatory asset register — documents, audits, certificates, NB correspondence — updated in real time?
5. Can you articulate the valuation step-up your current round is targeting, in terms of what the company will be worth after the milestone clears compared to today?
6. Is your reimbursement plan for at least one market budgeted and staffed, or is it a slide bullet?
7. Do you understand how the acquirers in your category price each regulatory asset individually, and have you built your spend to match?

## Frequently Asked Questions

**Why is MedTech valuation anchored to regulatory milestones rather than revenue?**
Because revenue in MedTech is gated by regulatory approval. A device above basic Class I cannot legally be sold in Europe without CE mark, and sustainable sales typically require reimbursement. The milestones are the conditions that unlock revenue, so specialist investors price them directly rather than waiting for the revenue to show up after the milestone clears.

**How much does CE mark add to enterprise value?**
It varies by category and device class, but CE mark is typically the largest single step-up in a MedTech company's valuation curve — a multiple rather than a percentage in most cases. The CE certificate issued under MDR Article 56 is a transferable asset that unlocks market access, and its absence is the largest single source of regulatory risk an investor can price.

**Is a CE certificate transferable in an acquisition?**
Yes, but not automatically. The acquirer either takes over the legal manufacturer role with the associated obligations, or the product is re-branded under the acquirer's existing quality system. Either path requires Notified Body involvement, QMS updates, and careful planning into the deal timeline. Founders should treat the transfer mechanics as part of the valuation conversation, not as a closing detail.

**What regulatory assets do acquirers value most?**
A live QMS under EN ISO 13485:2016+A11:2021, a clean and current technical file, a CE certificate with clear transfer mechanics, a working PMS system with real data, and a vigilance record without hidden findings. Acquirers price each of these by what it would cost them to build or rebuild — which is usually far more than founders assume.

**What is the biggest valuation mistake founders make?**
Pricing an early round at an inflated mark without the milestone progress to support the step-up at the next round. The higher mark feels like a win at signing, but the next round becomes a down round when the milestone slips. A cleaner lower mark at Series A is often worth more at exit than a proud higher mark that triggers a bridge at Series B.

**How do I plan a round against a milestone instead of against headcount?**
Start with the milestone the round will clear. Derive the specific work required to clear it. Size the work honestly, then double the estimate as buffer. The resulting number is the round size. Benchmark the post-money valuation against European MedTech comparables at the same regulatory stage, not against SaaS comparables at the same headcount.

## Related reading

- [CE Marking Cost for Startups: A Transparent Breakdown](/blog/ce-marking-cost-startup-transparent-breakdown) — the cost buckets that become transferable assets at exit.
- [The Subtract to Ship Framework for MDR](/blog/subtract-to-ship-framework-mdr) — the methodology behind spending every round against milestone progress.
- [Product-Market Fit for MedTech Startups](/blog/product-market-fit-medtech-startups) — the upstream work the valuation curve assumes.
- [Funding a MedTech Startup: The Complete Guide](/blog/funding-medtech-startup) — the pillar post covering the full funding arc.
- [Why MedTech Needs More Capital Than SaaS](/blog/medtech-more-capital-than-saas) — the capital math behind every round between milestones.
- [MedTech Business Models Explained](/blog/medtech-business-models) — the model choices that shape how acquirers value the company.
- [Pre-Seed and Seed Funding for MedTech](/blog/pre-seed-seed-funding-medtech) — the rounds that set up a cleanly raisable Series A.
- [Series A for MedTech Startups](/blog/series-a-medtech-startups) — the round where milestone framing first becomes load-bearing.
- [Grant Funding for European MedTech](/blog/grant-funding-european-medtech) — the non-dilutive capital that extends runway between milestones.
- [MedTech Startup Exit Strategy: M&A, IPO, and Strategic Partnerships](/blog/medtech-exit-strategy) — the exit conversation that every milestone is implicitly preparing for.
- [MedTech Angel Investors](/blog/medtech-angel-investors) — the earliest capital that underwrites the first milestones.
- [MedTech Convertible Notes and SAFEs](/blog/medtech-convertible-notes-safes) — the instruments that defer valuation until a milestone makes pricing easier.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 56 (certificates of conformity issued by notified bodies — the transferable regulatory asset at the centre of MedTech valuation). Official Journal L 117, 5.5.2017.
2. EN ISO 13485:2016 + A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes (the transferable QMS asset valued in every regulatory due diligence).

---

*This post is part of the Funding, Business Models and Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. MedTech valuation is not a smooth curve — it is a staircase, and each step is a regulatory milestone. Plan the round against the step, clear it cleanly, and the valuation takes care of itself.*

---

*This post is part of the [Funding, Business Models & Reimbursement](https://zechmeister-solutions.com/en/blog/category/funding-reimbursement) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*